{
    "clinical_study": {
        "@rank": "106052", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Experimental", 
                "description": "BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Experimental", 
                "description": "BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Experimental", 
                "description": "BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to compare how the body takes up and then eliminates the study\n      drug BCX4161 when it is taken orally as a hard gelatin capsule and as a soft gelatin\n      capsule. This study will also evaluate whether food has any effect on how the body takes up\n      BCX4161."
        }, 
        "brief_title": "A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hereditary Angioedema", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Body mass index 19 to 32 kg/m2 and a weight of at least 50 kg\n\n          -  Abide by study restrictions\n\n          -  Attend all study visits\n\n          -  Acceptable birth control measures\n\n        Key Exclusion Criteria:\n\n          -  Clinically significant medical history, current medical or psychiatric condition, ECG\n             finding, or laboratory/urinalysis abnormality\n\n          -  Activated partial thromboplastin time or prothrombin time outside of normal\n             laboratory limits\n\n          -  Pregnant or nursing\n\n          -  Recent history of alcohol abuse or positive drugs of abuse screen\n\n          -  Current smokers\n\n          -  Donation or loss of greater than 400 mL of blood within 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125162", 
            "org_study_id": "BCX4161-104"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment A", 
                "Treatment B", 
                "Treatment C"
            ], 
            "description": "Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose", 
            "intervention_name": "BCX4161", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "BCX4161", 
            "BioCryst", 
            "hereditary angioedema", 
            "relative bioavailability", 
            "kallikrein inhibitor"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ruddington", 
                    "country": "United Kingdom", 
                    "state": "Nottingham", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical Ltd"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single-dose, Randomized, 3-period, Crossover Study to Evaluate the Relative Bioavailability of BCX4161 Formulated as a Soft Gelatin Capsule to BCX4161 Formulated as a Hard Gelatin Capsule and the Effect of Food on BCX4161 Pharmacokinetics", 
        "overall_official": {
            "affiliation": "Quotient Clinical Ltd", 
            "last_name": "Joanne Collier", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Plasma pharmacokinetics to assess the relative bioavailability of BCX4161 soft gelatin capsules to hard gelatin capsules", 
            "safety_issue": "No", 
            "time_frame": "Pharmacokinetic parameters AUC0-inf, AUC0-t and Cmax generated after 24 hours of postdose blood sampling"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125162"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety and tolerability evaluated through assessments of adverse events, laboratory analyses, vital signs, ECGs, and physical examinations", 
                "safety_issue": "No", 
                "time_frame": "Screening through study completion (approximately 61 days)"
            }, 
            {
                "measure": "Plasma pharmacokinetics to assess the effect of food on BCX4161", 
                "safety_issue": "No", 
                "time_frame": "Pharmacokinetic parameters AUC0-inf, AUC0-t and Cmax generated after 24 hours of postdose blood sampling"
            }
        ], 
        "source": "BioCryst Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioCryst Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}